Buy CL Stock At $80?

Colgate-Palmolive (CL) stock has underperformed the S&P 500 this year, declining 12% due to slowing sales growth, weak pet care demand, and adverse foreign exchange impacts. Despite these challenges, the analysis suggests CL, trading around $80, presents a buying opportunity, citing its moderate valuation metrics (e.g., P/S 3.2x vs S&P 3.3x) and strong financial stability (13.6% Debt-to-Equity). While growth is currently weak, moderate profitability and an anticipated recovery in the pet care segment by 2026 offer potential upside, though investor reluctance to assign higher multiples for slow growth remains a noted risk.

Analysis

Colgate-Palmolive (CL) stock has significantly underperformed the broader market, declining 12% year-to-date while the S&P 500 has gained 13%. This divergence is driven by tangible headwinds, including a projected slowdown in organic sales growth to approximately 2% for 2025, persistent weakness in the pet care division, and unfavorable foreign exchange impacts. Despite these top-line challenges, which have seen revenue growth flatten to just 0.1% over the past twelve months, the company's financial health remains robust. Key indicators of strength include a high operating margin of 21.7%, well above the S&P 500 average of 18.6%, and a very strong balance sheet evidenced by a Debt-to-Equity ratio of only 13.6%. Furthermore, CL has demonstrated notable resilience during market downturns, with smaller peak-to-trough declines than the S&P 500 during the 2008, 2020, and 2022 crises. From a valuation perspective, the stock appears moderate, trading in line with the S&P 500 on P/E (22.2x) and P/FCF (19.1x) ratios, and slightly below its five-year average price-to-sales multiple. A potential catalyst for future growth is the anticipated recovery of the pet care business in 2026, which has been suppressed by post-pandemic inventory adjustments.

Key Decisions for Investors

• Given the stock's recent underperformance and a valuation that is now in line with the market and below its own historical average, investors could view the current price near $80 as a potential entry point for a defensive, long-term holding.
• Investors should closely monitor for signs of a recovery in the pet care segment and any acceleration in organic sales growth, as a failure to improve the top line is the primary risk that could keep the stock's valuation multiple suppressed.
• For portfolios focused on capital preservation and lower volatility, CL's historically strong performance during market downturns and its robust balance sheet make it a candidate to consider for adding defensive stability.